# Elite Pharmaceuticals Inc (ELTP)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/elite-pharmaceuticals-inc/ JSON: https://steadybase.io/company/elite-pharmaceuticals-inc.json Checked Nov 10, 2026. Latest filing read: Aug 13, 2026.

## Company

- Legal name: ELITE PHARMACEUTICALS INC /NV/
- Ticker: ELTP (OTC)
- SEC CIK: 0001053369
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Northvale, NJ
- Fiscal year ends: March 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: elitepharma.com
- LinkedIn: https://www.linkedin.com/company/elite-pharmaceuticals-inc-
- Next earnings date: Nov 14, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $148.9M for the fiscal year ended Mar 31, 2026 (10-K filed Jun 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/0001493152-26-031070-index.html
- Operating income: $49.1M for the fiscal year ended Mar 31, 2026 (10-K filed Jun 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/0001493152-26-031070-index.html
- Net income: $44.9M for the fiscal year ended Mar 31, 2026 (10-K filed Jun 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/0001493152-26-031070-index.html
- SG&A: $17.6M for the fiscal year ended Mar 31, 2026 (10-K filed Jun 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/0001493152-26-031070-index.html
- Employees: 65 as of Jun 25, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm
- Shares outstanding: 1,077,136,442 as of Aug 13, 2026 (10-Q filed Aug 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226037752/0001493152-26-037752-index.html
- Auditor: Forvis Mazars, LLP, Iselin, NJ, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm

## Business

, a Nevada corporation (the “Company”, “Elite”, “Elite Pharmaceuticals”, the “registrant”, “we”, “us” or “our”) was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary, Elite Laboratories, Inc. (“Elite Labs”), was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Mar 31, 2026 | $148.9M | $49.1M | $44.9M | $17.6M |
| Mar 31, 2025 | $84.0M | $19.6M | -$4.3M | $9.0M |
| Mar 31, 2024 | $56.6M | $10.8M | $20.1M | $7.1M |
| Mar 31, 2023 | $34.2M | $3.7M | $3.6M | $5.1M |
| Mar 31, 2022 | $32.3M | $5.1M | $8.9M | $4.5M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/elite-pharmaceuticals-inc.json

## Officers and directors

- Nasrat Hakim, President, Chief Executive Officer and Chairman of the Board of Directors. Source: 10-K filed Jun 29, 2026, https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm
- Carter Ward, Chief Financial Officer. LinkedIn: https://linkedin.com/in/carterjward. Source: 10-K filed Jun 29, 2026, https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm
- Douglas Plassche, Executive Vice President of Operations. Source: 10-K filed Jun 29, 2026, https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm
- Kirko Kirkov, Chief Commercial Officer. Source: 10-K filed Jun 29, 2026, https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm
- Barry Dash, Director. Source: 10-K filed Jun 29, 2026, https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm
- Davis Caskey, Director. Source: 10-K filed Jun 29, 2026, https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm
- Jeffrey Whitnell, Director. Source: 10-K filed Jun 29, 2026, https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm

## Recent 8-K events

- Nov 3, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226049707/form8-k.htm
- Aug 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226037787/form8-k.htm
- Aug 10, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226036905/form8-k.htm
- Aug 4, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226035922/form8-k.htm
- Jun 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226031103/form8-k.htm
- Jun 23, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226029700/form8-k.htm
- Jun 15, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226028610/form8-k.htm
- Jun 1, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/form8-k.htm
- Apr 2, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226014813/form8-k.htm
- Feb 17, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226007190/form8-k.htm

## Insider trades (Form 4)

- Oct 9, 2026: Barry H. Dash (Director) bought 100,000 shares, about $25,980. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315226047486/0001493152-26-047486-index.htm
- Aug 19, 2026: Barry H. Dash (Director) bought 30,000 shares, about $8,700. Source: https://www.sec.gov/Archives/edgar/data/1053369/000132422226000001/0001324222-26-000001-index.htm
- Oct 2, 2025: Douglas Plassche (EVP Operations) sold 800,000 shares, about $496,000. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315225016979/0001493152-25-016979-index.htm
- Aug 22, 2025: Pharmaceuticals Inc /Nv/ Elite (EVP Operations) sold 500,000 shares, about $260,000. Source: https://www.sec.gov/Archives/edgar/data/1053369/000149315225012347/0001493152-25-012347-index.htm
- Jul 10, 2025: Kirko Kirkov (Chief Commercial Officer) bought 16,366 shares, about $9,656. Source: https://www.sec.gov/Archives/edgar/data/1053369/000194604325000002/0001946043-25-000002-index.htm
- Jul 8, 2025: Douglas Plassche (EVP Operations) sold 200,000 shares, about $116,000. Source: https://www.sec.gov/Archives/edgar/data/1053369/000164117225018593/0001641172-25-018593-index.htm

## Latest filings

- 8-K filed Nov 3, 2026: https://www.sec.gov/Archives/edgar/data/1053369/000149315226049707/form8-k.htm
- 10-K filed Jun 29, 2026: https://www.sec.gov/Archives/edgar/data/1053369/000149315226031070/form10-k.htm
- 10-Q filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/1053369/000149315226037752/form10-q.htm
- DEF 14A filed Apr 29, 2020: https://www.sec.gov/Archives/edgar/data/1053369/000121390020010470/ea121205-def14a_elitepharma.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/